PH

Paul J. Hastings

Director at ViaCyte

Mr. Hastings, who is currently President and Chief Executive Officer (CEO) of Nkarta Therapeutics, has more than 35 years of leadership experience in biopharmaceuticals. Previous to Nkarta, he was Chairman and Chief Executive Officer (CEO) at OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, he served as CEO of QLT, Inc. Before QLT, Mr. Hastings served as President and CEO of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, he served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and CEO of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe and President, Genzyme Therapeutics. Mr. Hastings also held senior Marketing and Sales positions for Synergen, Inc. and Hoffmann-La Roche. He is currently Lead Director of Pacira Pharmaceuticals, Chair of the Board at Proteon Therapeutics, Director of Nkarta Therapeutics, and Vice Chair of the Biotechnology Innovation Organization (BIO). Mr. Hastings received a B.S. in Pharmacy from the University of Rhode Island.

Timeline

  • Director

    Current role